Publications by authors named "J F Ovalles"
Objectives: We aimed to investigate the association between the different antiphospholipid antibodies (aPL) and both systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) manifestations.
Methods: Patients from the RELESSER registry, a Spanish retrospective, cross-sectional, forty-five hospital registry of adult SLE patients, were included.
Results: Out of a total of 3,658 SLE patients, 1372 were aPL positive (555 of them fulfilled criteria for APS).
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality.
Lupus
October 2020
Introduction: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in systemic lupus erythematosus(SLE) patients. Our aim was to investigate the differences between SLE patients according to the presence of aPL and/or clinical antiphospholipid syndrome (APS).
Materials And Methods: Patients from the RELESSER-T registry were included.
Article Synopsis
- A study looked at serious infections in kids with a disease called juvenile-onset systemic lupus erythematosus (jSLE).
- They found that about 30% of these kids had serious infections during the study, with the most common type being respiratory infections caused by bacteria.
- The risk of getting these serious infections was higher in kids who had more disease symptoms, used certain medicines to suppress their immune system, or had surgery to remove their spleen.
To describe the clinical and therapeutic management of rheumatoid arthritis (RA) patients with biological disease-modifying antirheumatic drugs (bDMARDs), alone or in combination with conventional synthetic DMARDs (csDMARDs), as well as analysing changes over time in bDMARD use. An observational, retrospective, multicentre study was conducted in the rheumatology departments of 10 public Spanish hospitals. Patients with RA treated with bDMARDs at baseline who had medical records available in the data collection period 2013-2016 were included.
View Article and Find Full Text PDFResponse to treatment of rheumatoid arthritis shows large inter-individual variability. This heterogeneity is observed with all the anti-rheumatic drugs, including the commonly used TNF inhibitors. It seems that drug-specific and target-specific factors lead individual patients to respond or not to a given drug, although this point has been challenged.
View Article and Find Full Text PDF